Recon: Lilly plans $6.5B Texas API site; Moderna says updated COVID jab induces strong immune response

• Trump, questioning vaccine safety, pushes major changes to how kids get shots (STAT)
• Citing possible link to autism, Trump urges limiting use of Tylenol during pregnancy (STAT)
• Tylenol-maker Kenvue shares bounce back, Trump claims face pushback (Reuters)
• What the evidence tells us about Tylenol, leucovorin, and autism (STAT)
• FDA aims to expand use of leucovorin as RFK Jr. touts it as autism treatment (STAT)
• FDA hands Scholar Rock a CRL for spinal muscular atrophy drug (Endpoints)
• FDA rejects Rexulti-Zoloft combo for PTSD (Endpoints)

• Countering Trump, European health officials stress that acetaminophen is safe to use during pregnancy (STAT)
• EU, WHO counter Trump's warnings on autism and pregnancy (Reuters)
• Post-Hoc: Threatening the UK to send a message to the rest of Europe (Endpoints)
• Invivo aims to raise €100M for fourth fund; SEED Therapeutics gets $30M (Endpoints)
• Chinese police investigating app fraud case, says German drugmaker Merck KGaA (Reuters)
• Emeis Strikes Deal With Investors to Cut Debt by €700 Million (Bloomberg)
• UK MHRA: Gene Therapy Manufacturing Methods Need ‘Urgent Harmonization’ (Pink Sheet)

• Bristol Myers said its next-gen multiple myeloma drug cut rates of detectable cancer. Will it get FDA approval? (STAT)
• Neurocrine details Phase 2 results for depression drug (Endpoints)
• Why Doximity wants to be the Bloomberg Terminal for doctors (Endpoints)
• Eli Lilly sells New Jersey site to Celltrion for $330M (Endpoints)
• Lilly reveals plans for $6.5B API production facility in Texas (Fierce Pharma)
• Ionis says RNA drug for rare brain disorder succeeded pivotal trial, plans to ask for FDA approval (Endpoints)
• Moderna says updated next-generation COVID shot shows strong immune response in patients (Reuters)
• Tylenol-maker Kenvue shares bounce back, Trump claims face pushback (Reuters)
• Biotech Real Estate Slump Has MIT’s Hometown Seeking Backups (Bloomberg)

• J&J to withdraw acid reflux device from certain markets (Reuters)
• Multi-cancer blood tests aren’t ready for routine use, review says (MedTech Dive)
• Olympus removes needles after patient death (MedTech Dive)
• Sava Technologies Microsensing Milestone: 10 Days Continuous Wear, No Finger-Prick Calibration (MedTech Insight)
• INBRAIN, Mayo Clinic To Test BCI With Standard Deep Brain Stimulation In Parkinson’s Patients (MedTech Insight)

• The wellness industry needs to stop scaring people (Food Dive)
• Suspected botulism case prompts French warning (Food Safety News)

• Longevity Science and Healthspan Hype Is Exhausting. Try a Lil Cheat Instead (Bloomberg)
• White House asks Supreme Court to uphold Trump’s tariff powers (MedTech Dive)
• 340B Reform Advocates Hail CBO Report, But ‘Scoreable’ Savings Still In Doubt (Pink Sheet)
• Trump Upends Shutdown Talks With Democrats as Deadline Nears (Bloomberg)